Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS

Cancer Genetics and Cytogenetics

Volumn 193, Issue 2, 2009, Pages 78-85

  Slovak, Marilyn L ^a   O'Donnell, Margaret ^b   Smith, David D ^c   Gaal, Karl ^d  

^a City of Hope   (United States)

^b Division of Hematology and Hematopoietic Cell Transplantation   (United States)

^c Division of Information Sciences   (United States)

^d City of Hope   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLAST CELL; CHILD; CHROMOSOME 1Q; CHROMOSOME 7P; CHROMOSOME 7Q; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 7; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 68149160596     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.04.013     Document Type: Article

References (30)

1. Wang L., Ogawa S., Hangaishi A., Qiao Y., Hosoya N., Nanya Y., Ohyashiki K., Mizoguchi H., and Hirai H. Molecular characterization of the recurrent unbalanced translocation der(1;7)(q10;p10). Blood 102 (2003) 2597-2604
2. Huret JL. t(1;7)(q10;p10). Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available at: http://www.AtlasGeneticsOncology.org/Genes/t0107ID1003.html. Accessed January 2009.
3. Horiike S., Taniwaki M., Misawa S., Nishigaki H., Okuda T., Yokota S., Kashima K., Inazawa J., and Abe T. The unbalanced 1;7 translocation in de novo myelodysplastic syndrome and its clinical implication. Cancer 65 (1990) 1350-1354
4. Hsiao H.H., Sashida G., Ito Y., Kodama A., Fukutake K., Ohyashiki J.H., and Ohyashiki K. Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10). Cancer Genet Cytogenet 165 (2006) 161-166
5. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., and Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
6. Sanada M., Uike N., Ohyashiki K., Ozawa K., Lili W., Hangaishi A., Kanda Y., Chiba S., Kurokawa M., Omine M., Mitani K., and Ogawa S. Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms. Leukemia 21 (2007) 992-997
7. So C.C., Ma E.S., Wan T.S., Yip S.F., and Chan L.C. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms. Leuk Res 32 (2008) 1000-1001
8. Shaffer L., and Tommerup N.E. An International System for Human Cytogenetic Nomenclature (2005), Karger, Basel, Switzerland
9. In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., and Vardiman J.W. (Eds). World Health Organization of Tumors of Haematopoietic and Lymphoid Tissues. The Myelodysplastic Syndromes/Neoplasms. Chapter 5 (2009), IARC, Lyon 87-104
10. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., and Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
11. Song W.J., Sullivan M.G., Legare R.D., Hutchings S., Tan X., Kufrin D., Ratajczak J., Resende I.C., Haworth C., Hock R., Loh M., Felix C., Roy D.C., Busque L., Kurnit D., Willman C., Gewirtz A.M., Speck N.A., Bushweller J.H., Li F.P., Gardiner K., Poncz M., Maris J.M., and Gilliland D.G. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23 (1999) 166-175
12. Christiansen D.H., Andersen M.K., and Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 104 (2004) 1474-1481
13. Harada H., Harada Y., Niimi H., Kyo T., Kimura A., and Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103 (2004) 2316-2324
14. Roumier C., Fenaux P., Lafage M., Imbert M., Eclache V., and Preudhomme C. New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia 17 (2003) 9-16
15. Christiansen D.H., Andersen M.K., Desta F., and Pedersen-Bjergaard J. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 19 (2005) 2232-2240
16. Ma S.K., Wong K.F., Chan J.K., and Kwong Y.L. Refractory cytopenia with t(1;7),+8 abnormality and dysplastic eosinophils showing intranuclear Charcot-Leyden crystals: a fluorescence in situ hybridization study. Br J Haematol 90 (1995) 216-218
17. Imai Y., Yasuhara S., Hanafusa N., Ohsaka A., Enokihara H., Tomizuka H., Sonoyama M., Miura Y.S., Tohda S., Nara N., and Takahashi A. Clonal involvement of eosinophils in therapy-related myelodysplastic syndrome with eosinophilia, translocation t(1;7) and lung cancer. Br J Haematol 95 (1996) 710-714
18. Forrest D.L., Horsman D.E., Jensen C.L., Berry B.R., Dalal B.I., Barnett M.J., and Nantel S.H. Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): confirmation of eosinophil clonal involvement by fluorescence in situ hybridization. Cancer Genet Cytogenet 107 (1998) 65-68
19. Bernasconi P., Klersy C., Boni M., Cavigliano P.M., Calatroni S., Giardini I., Rocca B., Zappatore R., Caresana M., Quarna J., Lazzarino M., and Bernasconi C. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 19 (2005) 1424-1431
20. Sole F., Luno E., Sanzo C., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Cigudosa J.C., Milla F., Ribera J.M., Bureo E., Marquez M.L., Arranz E., and Florensa L. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90 (2005) 1168-1178
21. Pozdnyakova O., Miron P.M., Tang G., Walter O., Raza A., Woda B., and Wang S.A. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 113 (2008) 3331-3340
22. Lee D.S., Kim S.H., Seo E.J., Park C.J., Chi H.S., Ko E.K., Yoon B.H., Kim W.H., and Cho H.I. Predominance of trisomy 1q in myelodysplastic syndromes in Korea: is there an ethnic difference? A 3-year multi-center study. Cancer Genet Cytogenet 132 (2002) 97-101
23. Adeyinka A., Wei S., and Sanchez J. Loss of 17p is a major consequence of whole-arm chromosome translocations in hematologic malignancies. Cancer Genet Cytogenet 173 (2007) 136-143
24. Djordjevic V., cic-Fekete M., Jovanovic J., Drakulic D., Stevanovic M., Jankovic G., and Gotic M. Pattern of trisomy 1q in hematological malignancies: a single institution experience. Cancer Genet Cytogenet 186 (2008) 12-18
25. Haase D., Germing U., Schanz J., Pfeilstocker M., Nosslinger T., Hildebrandt B., Kundgen A., Lubbert M., Kunzmann R., Giagounidis A.A., Aul C., Trumper L., Krieger O., Stauder R., Muller T.H., Wimazal F., Valent P., Fonatsch C., and Steidl C. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110 (2007) 4385-4395
26. Mohamedali A., Gaken J., Twine N.A., Ingram W., Westwood N., Lea N.C., Hayden J., Donaldson N., Aul C., Gattermann N., Giagounidis A., Germing U., List A.F., and Mufti G.J. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110 (2007) 3365-3373
27. Gondek L.P., Tiu R., O'Keefe C.L., Sekeres M.A., Theil K.S., and Maciejewski J.P. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111 (2008) 1534-1542
28. Wang L., Fidler C., Nadig N., Giagounidis A., la Porta M.G., Malcovati L., Killick S., Gattermann N., Aul C., Boultwood J., and Wainscoat J.S. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica 93 (2008) 994-1000
29. Pellagatti A., Cazzola M., Giagounidis A.A., Malcovati L., Porta M.G., Killick S., Campbell L.J., Wang L., Langford C.F., Fidler C., Oscier D., Aul C., Wainscoat J.S., and Boultwood J. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 108 (2006) 337-345
30. Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol 142 (2008) 695-708